SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

The community is intensely debating a potential upcoming SpaceX IPO, with widespread skepticism regarding valuations and fears that retail investors are being positioned as exit liquidity for a massive pump-and-dump scheme. While some traders are actively scouting for alternative "proxy" stocks in the aerospace and satellite sectors to capture sector-wide momentum, others are deeply concerned about the sustainability of current space-tech valuations and the impact of extreme hype on market stability.

noice

NOICE is trending as traders speculate on its potential for volatility and explosive growth, fueled by its status as a nanocap meme token and recent appearances on trending gainers lists. The community is actively debating its technical setup, sharing hopes for further exchange visibility, and discussing broader market sentiment regarding altcoin season and upcoming regulatory developments.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quant is currently trending due to its pivotal role in institutional pilot projects, including tokenized deposit initiatives with major global banks. The community is heavily focused on its extremely low supply and perceived utility as essential infrastructure for real-world asset tokenization.

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

United Therapeutics Corp

United Therapeutics is experiencing significant market activity driven by positive Phase 3 data for Tyvaso in idiopathic pulmonary fibrosis, which analysts view as a major expansion of its addressable patient population. The community is actively debating the company's long-term competitive positioning against rival inhaled therapies and potential acquisition rumors within the broader respiratory and organ manufacturing sectors.

Glass House Brands, Inc. operates as an integrated cannabis company in the United States with focus on the California market and building brands to serve consumers across various segments. The company is involved in greenhouse cultivation operations, manufacturing practices, brand-building, and retailing activities. The company offers its cannabis products through its portfolio of brands, which includes Glass House Farms, PLUS Products, Allswell, Forbidden Flowers, and Mama Sue Wellness. The company was founded by Kyle Kazan, Graham Farrar and Jocelyn Rosenwald in 2015 and is headquartered in Long Beach, CA.

Glass House Brands Inc - Ordinary Shares (sub voting)

Glass House Brands

Glass House Brands is facing intense community scrutiny regarding potential labor and regulatory issues following reports of recent enforcement actions at cultivation facilities. While some investors remain optimistic about the company's long-term production scale and competitive cost structure in the California market, others are increasingly concerned about operational stability and the potential impact on future growth.

iShares Trust - iShares J.P. Morgan USD Emerging Markets Bond ETF

iShares J.P. Morgan USD Emerging Markets Bond ETF

EMB is trending as traders closely watch emerging market sovereign bond performance amid broader fixed income momentum shifts and cooling inflationary pressure. The community is actively discussing the ETFs role as a diversification tool for income generation, with heightened focus on its price action relative to U.S. Treasuries and potential spread carry opportunities.

Fox Corp. engages in providing television production and broadcasting services. It also provides news under the brands FOX News Media, FOX Sports, FOX Entertainment and FOX Television Stations, and Tubi Media Group. It operates through the following segments: Cable Network Programming, Television, and Other and Corporate. The Cable Network Programming segment refers to the production and licensing of news and sports content distributed primarily through traditional cable television systems, direct broadcast satellite operators, and telecommunication companies and online multi-channel video programming distributors. The Television segment focuses on the acquisition, marketing, and distribution of broadcast network programming. The Other and Corporate segment relates to the FOX Studio Lot, Credible Labs Inc, corporate overhead costs, and intracompany eliminations. The company was founded by Keith Rupert Murdoch on May 3, 2018, and is headquartered in New York, NY.

Fox Corporation - Ordinary Shares - Class B

Fox Corporation - Class B

Fox Corporation is seeing heightened discussion as shareholders navigate the company's evolving programming strategy and leadership changes following recent high-profile defamation settlements. Investors are closely monitoring its performance against media peers while community sentiment remains divided over its editorial direction and competitive position in the streaming landscape.

Avantor, Inc. is a life science tools company that engages in providing mission-critical products and services to the life sciences and advanced technology industries. Its portfolio includes biopharma, healthcare, education and government, as well as advanced technologies and applied materials industries. It sells materials, equipment, instrumentation, and offers specialty procurement. The company operates through the Laboratory Solutions segment and Bioscience Production. The Laboratory Solutions segment focuses on research, diagnostic, and quality control workflows. The Bioscience Production segment focuses on high-purity materials for bioprocessing and medical technologies. Avantor was founded by John Townsend Baker in 1904 and is headquartered in Radnor, PA.

Avantor Inc.

Avantor is gaining traction as investors speculate on potential M&A activity and leadership changes, with sentiment increasingly shifting toward a 'proof-over-potential' approach after mixed financial results. The community is closely watching insider buying trends and the impact of activist involvement on the company's long-term valuation.

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Neogenomics Inc.

Neogenomics is trending as investors react to a string of positive analyst upgrades and strong earnings results, which have reinforced confidence in its oncology testing platform and expanded market opportunities. The community is actively discussing the stock's potential for further re-rating, with many focusing on raised guidance, the launch of new cancer-tracking tests, and the possibility of the company becoming an attractive acquisition target.

What is DAG? In more traditional blockchains, the host provides the food/drinks (i.e resources) for this party. And when the guests arrive, the amount of resources can only accommodate so many people, the portions are small and then everything eventually runs out and the party ends. Think Constellation DAG like a potluck (a party where everyone brings food/drinks). With every added guest (node to the network), the more resources the party has to keep going. This is the nature of Constellation, a distributed system that scales horizontally.  Is Constellation a Blockchain? Not exactly. Although inspired by the principles of decentralization, many standard blockchains such as Bitcoin and Ethereum face scalability issues. This is why the next, generation of decentralized networks such as Hashgraph, IOTA, and Constellation have turned to DAG.  What is a Microservice? “Microservices” is an approach to application development in which a large application is built as a suite of modular services. Each module supports a specific business goal and uses a simple, well-defined interface to communicate with other sets of services. Uber, for example, is not a singular app purse. It is a unified app which means it is a single interface that brings together their driver app, their rider app, and their corporate team app.

Constellation

Constellation (DAG) is trending as traders speculate on the potential enterprise and market impact of the upcoming Nasdaq listing of AI Holdings (AIAI), which acquired Constellation Network assets. The community is focused on the project's pivot toward institutional data infrastructure, defense-grade validation, and the broader convergence of blockchain with AI commercialization.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>H.C. Wainwright upgraded Celcuity to ‘Buy’ from ‘Neutral’ and raised its price target to $165 from $94, citing positive Phase 3 trial results.</li><li>Citizens raised its price target for Celcuity to $160 from $150 and maintained an ‘Outperform’ rating.</li><li>The firm highlighted expected progression-free survival of 11–12 months for the triplet regimen and stronger-than-anticipated efficacy from the doublet versus control.</li></ul>Celcuity Inc. (CELC) could become an acquisition target in the oncology space, according to analysts, after the company reported positive results in the Phase 3 trial of its breast cancer therapy.According to TheFly, analysts at HC Wainwright expressed optimism about the company’s prospects after Celcuity’s breast cancer therapy, gedatolisib, achieved its primary endpoint in a Phase 3 trial.<a href="https://stocktwits.com/symbol/CELC">Celcuity shares</a> were up more than 15% in Monday’s pre-market trade, extending the gains from Friday. If CELC stock ends Monday’s regular trading session with these gains, it would be the stock’s best single-day gain in more than six months.Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.<h2 class="st-heading-2">Why Are Analysts Optimistic?</h2>Analysts at H.C. Wainwright upgraded Celcuity to ‘Buy’ from ‘Neutral’ and raised their price target to $165 from $94, citing positive Phase 3 trial results. The firm said gedatolisib has the potential to be a “game-changing” treatment for HR+/HER2- advanced breast cancer and could position Celcuity as an acquisition target.Citizens raised its price target for Celcuity to $160 from $150 and maintained an ‘Outperform’ rating. The firm said the data suggest the drug could expand its use in second-line ER+/HER2- advanced breast cancer, demonstrating benefit regardless of PI3K mutation status.It also pointed to expected progression-free survival of 11–12 months for the triplet regimen and stronger-than-anticipated efficacy from the doublet versus control.Stifel analyst Stephen Willey raised the firm’s price target on Celcuity to $150 from $125 and maintained a ‘Buy’ rating. Willey said the “statistically significant and clinically meaningful” improvement in the Phase 3 trial was largely expected, but noted that its selection as a late-breaking oral presentation at the ASCO Annual Meeting on June 2 was the bigger surprise.<h2 class="st-heading-2">Celcuity’s Latest Announcement</h2>Celcuity reported positive Phase 3 results for gedatolisib plus fulvestrant, with or without palbociclib, in patients with HR+/HER2- advanced breast cancer after prior CDK4/6 and aromatase inhibitor treatment.The company stated that the gedatolisib triplet regimen met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival compared with alpelisib plus fulvestrant.The gedatolisib doublet also delivered a statistically significant PFS benefit compared with the control arm, despite being a secondary endpoint; both regimens demonstrated manageable safety profiles with no new safety concerns.HR+/HER2- breast cancer is the most common form of the disease, representing about 70% of all cases. Within this group, roughly 40% of patients carry PIK3CA mutations.<a href="https://stocktwits.com/symbol/CELC">CELC stock</a> is up 26% year-to-date and 1,063% over the past 12 months. The Tema Oncology ETF (CANC) is up 50% over the past 12 months, while the S&amp;P Biotech ETF (XBI) is up 58%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/gamestop-ryan-cohen-ebay-build-larger-business-gme-ebay-stock/cZQMpRjReJc">GameStop's Ryan Cohen Says He Plans On Bringing An Entrepreneurial Mindset To eBay And Building Something 'Much Larger'</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Celcuity logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Wall Street Believes Celcuity Could Become An Acquisition Target – Why This Analyst Raised Their Price Target By A Whopping 76%

H.C. Wainwright expressed optimism about the company’s prospects after Celcuity’s breast cancer therapy achieved its primary endpoint in a Phase 3 trial.

Equity

Here's Why Biotech ETFs Are Rallying Hard 

Biotech rally gains steam on valuations, rate cuts, FDA wins & M&A. IBB, XBI, CANC and IDNA are ETFs near one-year highs.

<ul class="summary-bullets"><li>94% of participants achieved CRP levels below 2 mg/L, a threshold associated with lower cardiovascular risk.</li><li>Safety data were favorable, with adverse events that were mild to moderate, self-resolving, and not dose-dependent.</li><li>The company expects partner Novartis to begin multiple Phase 2 studies of MRT-6160 in immune-mediated diseases.</li></ul>Shares of Monte Rosa Therapeutics (GLUE) surged more than 50% in pre-market trading on Wednesday after the company reported positive interim Phase 1 data for MRT-8102, highlighting strong anti-inflammatory effects in subjects with elevated cardiovascular disease risk.<a href="https://stocktwits.com/symbol/GLUE">GLUE stock</a> is on track to open at its highest level in more than four years.<h2 class="st-heading-2">Phase – 1 Highlights</h2>The NEK7-directed molecular glue degrader produced rapid and durable reductions in systemic inflammation, with C-reactive protein (CRP) levels falling by 85% after four weeks of treatment. Notably, 94% of participants achieved CRP levels below 2 mg/L, a threshold associated with lower cardiovascular risk.The randomized, placebo-controlled study included single and multiple ascending doses, as well as a Part 3 cohort enrolling subjects with obesity and elevated CRP. Across doses ranging from 5 mg to 400 mg, MRT-8102 demonstrated deep and sustained NEK7 degradation of roughly 80% to 90%.&nbsp;The treatment also led to significant reductions in inflammatory markers. Safety data were favorable, with adverse events that were mild to moderate, self-resolving, and not dose-dependent, and no increased risk of infection was observed.Based on these results, Monte Rosa has expanded the ongoing GFORCE-1 study to multiple dose levels, with additional data expected in the second half of 2026. The company plans to initiate a Phase 2 study in atherosclerotic cardiovascular disease later this year, while continuing to explore additional inflammatory and oncology indications.Monte Rosa also outlined several upcoming milestones across its immunology, inflammation, and oncology programs. It expects partner Novartis to begin multiple Phase 2 studies of MRT-6160 in immune-mediated diseases and plans to submit an investigational new drug (IND) application&nbsp;for a next-generation NEK7 program in 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, amid ‘extremely high’ message volumes. GLUE was among the top trending tickers on the platform.<figure class="image"><img src="https://news.stocktwits-cdn.com/GLUE_jpg_c79d022259.webp" alt="GLUE.jpg" width="937" height="99"><figcaption>GLUE's Sentiment Meter and Message Volumes at Premarket on Jan. 7, 2026 | Source: Stocktwits</figcaption></figure>One user sees a strong rally if the stock can overcome resistance at $28.<stembedurl>https://stocktwits.com/MuchMillions/message/641056765</stembedurl>Over the past year, the stock has gained more than 120%.Read Also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-first-solar-stock-fall-5-in-premarket-today/cmxyC2bR4cD">Why Did First Solar Stock Fall 5% In Premarket Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did GLUE Stock Surge Over 50% In Premarket Today?

Monte Rosa Therapeutics reported positive interim Phase 1 data for MRT-8102, showing significant anti-inflammatory effects in patients with elevated cardiovascular risk.

Temas Oncology ETF (CANC) Surpasses $100m in Assets Amidst Strong 2025 Performance

Tema ETFs (Tema), the New York-based manager of innovative exchange-traded funds (ETFs), is pleased to announce the Tema Oncology ETF (CANC) has surpassed $100m in assets under management (AUM) two...

Be Thankful to These ETFs This Year 

Be thankful for this year's resilient ETFs -- BWET, LITP, PINK and CANC -- which shined despite volatility, tariffs, AI worries and Fed shifts.

<ul class="summary-bullets"><li>Aucatzyl will be available through routine commissioning by the NHS, the company said.</li><li>Aucatzyl was approved by the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in November 2024.</li><li>The company also intends to launch Aucatzyl in England and Wales soon, It added.</li></ul> Autolus Therapeutics Plc (AUTL) said on Tuesday that the UK’s National Institute for Health and Care Excellence (NICE) has published draft guidance recommending its Aucatzyl CAR T cell therapy for use in the National Health Service (NHS) in England and WalesShares of the company rose 14% in the premarket session at the time of writing.<h2 class="st-heading-2">UK Approval And Recommendation</h2>NICE has recommended that Aucatzyl be used as a treatment option for adult patients aged 26 years or older with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://autolus.gcs-web.com/news-releases/news-release-details/nice-recommends-aucatzylr-obecabtagene-autoleucel-treatment">said</a>. Relapsed or refractory B-cell precursor acute lymphoblastic leukemia is a cancer that either returns after treatment or never responded to initial therapy.Aucatzyl will be available through routine commissioning by the NHS, the company said. The company also intends to launch Aucatzyl in England and Wales soon, it added.Aucatzyl or obecabtagene autoleucel is an autologous CD19 CAR T cell therapy. Autologous CD19 CAR T-cell therapy is an immunotherapy that uses a patient's own T-cells, which are genetically modified to target and attack cells that express the CD19 protein. This treatment has shown high efficacy in relapsed or refractory B-cell malignancies.The U.S. Food and Drug Administration approved Aucatzyl for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in November 2024. A conditional marketing authorization from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) followed in April 2025.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around AUTL stayed within the ‘bearish’ territory over the past 24 hours, while message volume jumped from ‘low’ to ‘normal’ levels.A Stocktwits user sees the stock hitting as high as $2.50.<stembedurl>https://stocktwits.com/nader_1/message/637361441</stembedurl>Another applauded the recent announcement and expressed hope that cell therapy would become the standard of care.<stembedurl>https://stocktwits.com/janed102/message/637360741</stembedurl><a href="https://stocktwits.com/symbol/AUTL">AUTL stock</a> is down by 47% this year and by about 58% over the past 12 months. &nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-keys-stock-surge-14-in-premarket-today/cL52hzFREX8">Why Did KEYS Stock Surge 14% In Premarket Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

AUTL Stock Soars Pre-market On Positive Recommendation For Cell Therapy Targeting Cancer In UK

NICE has recommended that Aucatzyl be used as a treatment option for adult patients aged 26 years or older with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, the company said. 

Inside the Recent Strength in Biotech ETFs 

Biotech strength is back, with IBB, PBE, FBT, CANC and HELX climbing as cheaper valuations, rate-cut hopes, FDA approvals and strong deal activity fuel biotech gains.



Biotech ETFs Bounce Back in 2025: Here's Why  

Biotech ETFs rally. IBB, ARKG, SBIO, BBC, CANC and BBP soar as Fed rate cut optimism, FDA approvals, deals and cheaper valuations drive the space in 2025.

CANC
Tema Oncology ETF

Feed

News

Sentiment

Fundamentals

Info

Compact View

Latest CANC News

CANCTema Oncology ETF